Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Data transparency initiatives 'could deter industry investment'

This article was originally published in SRA

Executive Summary

The pharmaceutical industry fears that early disclosure of clinical data could impede sponsor efforts to secure patents, driving away potential investors in the process. But regulators say investors should welcome the initiatives because they will bring greater efficiency to drug development. Sue Sutter reports on the debate from the US Biotechnology Industry Organization's annual convention in Philadelphia.

Advertisement
Advertisement
UsernamePublicRestriction

Register

PS118271

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel